Filter By Category
Archives
Share on -
APITEGROMAB
Generic Name: APITEGROMAB
ABSTRACT -
Apitegromab is a monoclonal antibody that binds latent myostatin and is designed to increase muscle mass and function by selectively inhibiting myostatin activation.
It has been developed for spinal muscular atrophy and other muscle-wasting conditions.
Regulatory review has been ongoing, but an approved routine dosing label was not established at the time of preparation.
DOSAGE -
- Dosage should be determined only by a qualified healthcare professional.
- Clinical trials have evaluated intravenous administration at protocol-defined intervals and doses.
- No approved standard dosing regimen is established until a final regulatory label is available.
- Continue background SMA therapy only as directed by the treating specialist and protocol.
SIDE EFFECTS–
- Possible side effects may include:
- Headache
- Fever or chills
- Infusion reaction
- Nasopharyngitis or respiratory infection
- Fatigue
- Nausea
- Rash or pruritus
- Hypersensitivity
ALLERGIC REACTIONS -
- Hypersensitivity to the active biologic or formulation excipients is possible.
- Symptoms may include rash, urticaria, pruritus, facial swelling, bronchospasm, fever, chills, hypotension, or anaphylaxis.
- Patients with a suspected allergic reaction should stop treatment and seek urgent medical attention.
DRUG INTERACTIONS–
- Concomitant SMA therapies should be coordinated by neuromuscular specialists.
- Other biologics may increase immune or infusion-reaction risk.
- Live vaccines should be reviewed according to immunization guidance and protocol.
PREAUTIONS–
- Use in neuromuscular specialist settings.
- Monitor motor function, respiratory status, swallowing, and infusion reactions.
- Assess hypersensitivity history and intercurrent infections.
- Pregnancy and lactation safety are not established.
WARNINGS –
- Investigational or pending-regulatory-status biologic depending on jurisdiction.
- Serious hypersensitivity is possible.
- Do not use outside clinical-trial, access, or approved regulatory pathways.
Share on -
. Developed by